Melanoma, FISH, Tissue
Melanoma is a cancer of pigment-producing cells (melanocytes) that most frequently occurs in the skin, but can also occur in the eyes, ears, and gastrointestinal tract. Malignant melanoma is characterized by pigmented lesions and must be differentiated from non-cancerous moles. Melanomas can develop anywhere on the skin, but often start on the chest and back in men and on the legs in women. A major risk factor for melanoma is UV exposure, which damages the DNA of melanocytes. Other risk factors include having a weakened immune system, being male, and being older. Most cases of melanoma are due to somatic mutations and are not inherited. Somatic mutations in the BRAF and CDKN2A genes are some of the most common in sporadic melanoma. In about 10 percent of cases, melanoma risk is inherited in an autosomal dominant manner and most familial cases of melanoma are a result of variants in CDKN2A, variants in CDK4 and RB1. An estimated 8% of affected individuals also have a first-degree relative with melanoma and an estimated 1–2% of people with melanoma have two or more affected close relatives. Common genes associated with a hereditary predisposition to melanoma are:
Tumor Protein p53 (TP53): p53 protein plays significant roles in regulation of the cell cycle, DNA repair and programmed cells death. Germline TP53 pathogenic variants can lead to early onset of several cancers, including melanoma.
Phosphatase and Tensin homolog (PTEN): PTEN is a tumor suppressor gene that encodes a dual lipid and protein phosphatase. PTEN mutations cause Cowden syndrome and have been implicated in the development of melanoma.
BRCA2: is a tumor suppressor gene that is mainly associated with a high risk for breast and ovarian cancer. However, pathogenic variants in BRCA2 may occur in melanoma. The most commonly reported cancers after breast and ovarian with BRCA2 variants are pancreas, prostate and melanoma.
Microphthalmia-Associated Transcription Factor (MITF): is a melanoma oncogene that controls the expression of CDKN2A/p16(INK4a) which has important role in melanoma development.
CDK4: is a protein-serine kinase that allows for orderly progression through the cell cycle. Variants in CDK4 allow cells to skip the G1/S cell cycle checkpoint, thereby leading to uncontrolled cell proliferation. Alterations in CDK4 are responsible for a very small proportion of familial melanoma.
BRCA1-Associated Protein 1 (BAP1): the BAP1 gene encodes the deubiquitinating enzyme, nuclear ubiquitin carboxy-terminal hydrolase. BAP1 has roles in chromatin dynamics, DNA damage response and cell cycle regulation. Germline variants in BAP1 have been reported to cause several types of cancer including uveal melanoma, cutaneous melanoma, non-melanoma skin cancer, ovarian cancer, breast cancer, pancreatic cancer, lung cancer and meningiomas.
Retinoblastoma 1 (RB1): is a tumor suppressor gene and a negative regulator of the cell cycle through repression of transcription of genes needed in S-phase. Retinoblastoma is an autosomal dominant disorder, and about 40% of cases are inherited or caused by germline variants in the RB1 gene. Variants in the RB1 gene can also increase risk of melanoma..
CHEK2: is involved in recognizing double-strand breaks in DNA, and allows for activation of downstream targets, such as p53 and BRCA2. Variants in CHEK2 have been associated with melanoma. CHEK2 is upregulated in response to UV exposure, suggesting a role for the protein in control of UV damage.
POT1: The POT1 gene encodes a protein that is widely conserved across eukaryotic species and is associated with the telomere shelterin complex that protects telomeres by preventing incorrect processing of chromosome ends. POT1 variants may be associated with malignant melanoma.
Common genes associated with a somatic mutation in melanoma are BRAF, GNAQ, GNA11, KIT and NRAS. BRAF is a member of the RAF kinase family of growth signal transduction protein kinases that encodes the serine-threonine kinase. It plays a role in regulating the MAPK pathway.
NRAS is a member of RAS family of GTPases and the most commonly mutated isoform in melanoma.
GNAQ and GNA11 genes encode members of the q class G-protein α-subunits that mediate signals from G-protein-coupled receptors to the MAPK pathway.
KIT gene encodes the receptor tyrosine kinase. The activation of mutations in these genes lead to the constitutive activation of the RAS/RAF/MEK/ERK (MAPK) and the PI3K/PTEN/AKT (AKT) signaling pathways. Mutations in these genes are found in approximately 70% of melanomas.
Next generation sequencing is considered as an accurate, cost-effective method to identify mutations across numerous genes known to be associated with melanoma.
Panel Components Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes: BRAF, GNAQ, GNA11, KIT, NRAS, BAP1, BRCA2, CDK4, CDKN2A, CHEK2, MC1R, MITF, MUTYH, POT1, PTEN, RB1, SLC45A2, TP53, TYR associated with melanoma.
- Diagnostic confirmation of malignant melanoma
- Identification of a hereditary susceptibility to malignant melanoma
- Development a clinical surveillance plan for early melanoma detection
- Identification of at-risk family members
Positive
- At least one known pathogenic variant or mutation associated with melanoma cancer should be detected in the tested genes.
Negative
- No pathogenic variant or mutation detected in the tested genes.
Negative
Formalin-fixed, paraffin-embedded tissue blocks.
Stability
- Ambient- infinitely
- Cell Mol Life Sci. 2015;72: 1249-60. [PMID: 25433395]
- Nat Genet. 2014;46(5):482-6. [PMID: 24686846]
- Nature. 2011;480: 94-8. [PMID: 22012259]
- Nat Genet. 2011;43: 925-6. [PMID: 21956388]
- Annu Rev Pathol. 2009;4: 551-79. [PMID: 19400696]
- Genes Dev. 2006;20: 2149-82. [PMID: 16912270]
- Hered Cancer Clin Pract. 2004;2: 123-9. [PMID: 20233466]
- Cancer Res. 2003;63: 2881-90. [PMID: 12782594]
- Int J Cancer. 1998 Sep 25;78:13-5. [PMID: 9724087]
- Proc Natl Acad Sci U S A. 1996;93: 8541-5. [PMID: 8710906]
- Proc Natl Acad Sci U S A. 1983;80: 6071-5. [PMID: 6577466]